Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto harvest, because second-generation hybrid seeds are inferior. Nevertheless, most seed companies contract only with farmers who agree not to plant harvested seeds. Terminator technology has been developed by governmental labs, university researchers and companies. The technology has not been used commercially. Rumors that Monsanto and other companies intended to introduce terminator technology caused protests, for example in India. In 1999, Monsanto pledged not to commercialize terminator technology. The Delta & Pine Land Company of Mississippi intended to commercialize the technology, but D&PL was acquired by Monsanto in 2007. Monsanto developed several strains of genetically modified wheat, including glyphosate-resistant strains, in